Astria Therapeutics, Inc. (NASDAQ:ATXS)
Astria Therapeutics focuses on developing therapies for rare allergic and immunological diseases, notably STAR-0215 for hereditary angioedema. The company announced its participation in two upcoming investment conferences. CEO Jill C. Milne will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, and at the Ladenburg Thalmann 2022 Healthcare Conference on September 29. Both presentations will be available via live webcasts. Archived replays will be accessible for 30 days on their website. For more information, visit www.astriatx.com.